Classic Galactosemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Classic galactosemia, a Type I disorder stemming from deficiency in the galactose 1-phosphate uridylyltransferase (GALT) enzyme, is an inherited condition affecting galactose metabolism. The primary treatment approach currently utilized, a diet restricted in galactose, addresses the neonatal symptoms but does not entirely prevent chronic issues that may arise. Mutations within the GALT gene, located on chromosome 9p13, lead to classic galactosemia by disrupting the function of the galactose-1-phosphate uridyltransferase enzyme. Variants of this gene, such as the Duarte variant, are associated with varying levels of enzyme activity, resulting in milder or absent symptoms of galactosemia. Symptoms typically manifest when affected individuals consume breast milk or lactose-containing formula, leading to feeding difficulties, failure to thrive, and indications of liver damage such as jaundice, bleeding tendencies, and hypoglycemia. Without appropriate intervention, which primarily involves galactose restriction, there is a risk of sepsis (commonly from E-coli) and even neonatal mortality. Despite adherence to treatment protocols, long-term complications may arise, including cognitive deficits, motor impairments, ovarian dysfunction impacting fertility in women, and reduced bone density. Many nations include galactosemia screening as part of routine neonatal care. In cases where neonatal screening is absent, diagnosis relies on clinical presentation, which can be confirmed through metabolic assays, assessment of enzyme activity, and genetic analysis of the GALT gene. Differential diagnoses may involve conditions like galactose epimerase deficiency and other disorders leading to acute neonatal liver disease. Treatment primarily revolves around restricting galactose intake through diet, with infants typically being fed soy-based or lactose-free formulas. Lifelong adherence to this dietary regimen is recommended, supplemented with calcium, vitamin D, and vitamin K, to maintain bone health if dietary intake falls short of recommended levels. Regularly monitoring cognitive, motor, and gonadal function and bone mass is essential. Additionally, eye examinations are advisable, particularly in cases where neonatal cataracts are present or if dietary compliance is a concern. The prognosis hinges on factors such as the age of diagnosis, disease severity, and adherence to dietary restrictions, all of which influence the onset and progression of secondary complications.
Thelansis’s “Classic Galactosemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Classic Galactosemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Classic Galactosemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Classic Galactosemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment